Linkedin
RLS logo_header
Linkedin

TOP STORIES from the week

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

Vopimetostat and Daraxonrasib Demonstrated 92% ORR in Pancreatic Cancer

US FDA Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic NSCLC

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Ph 1 trial SERHEMA-1 of AOP208 initiated in AML/MDS patients

US FDA Approves INQOVI® in Combination with Venetoclax in AML Patients Ineligible for Intensive Induction Chemo

FDA accepts NDA for giredestrant in ER+ve early-stage breast cancer with positive Ph 3 results in the curative setting

Positive Mid-Year Interim Clinical Progress Reported from Ph 2 Study of Ampligen® (rintatolimod) + Imfinzi for the Treatment of Pancreatic Cancer

First Patient Dosed in Ph 3 Study of Bulumtatug Fuvedotin in TNBC Patients

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Stay up to date with OTW

Get all oncology clinical development news in your inbox

Drug approvals

Imfinzi approved in the US for patients with BCG-naïve, high-risk NMIBC

European Commission Authorizes Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in 1L CLL

DARZALEX® (daratumumab) injectable approved for administration by patients or caregivers for treatment of multiple myeloma

Opdivo in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

Regulatory news

US FDA Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic NSCLC

FDA accepts NDA for giredestrant in ER+ve early-stage breast cancer with positive Ph 3 results in the curative setting

Ori-C101  Receives NMPA Clearance for Confirmatory Ph 2 Trial in Late-Line Advanced HCC

FDA clears IND application for AMX-883 for AML

Trial results

Vopimetostat and Daraxonrasib Demonstrated 92% ORR in Pancreatic Cancer

Positive Mid-Year Interim Clinical Progress Reported from Ph 2 Study of Ampligen® (rintatolimod) + Imfinzi for the Treatment of Pancreatic Cancer

Preliminary Readout from Ph 1 Trial of uTREAT[®] in GBM announced

Lancet Oncology publishes results of Pivotal Ph 3 Significant DFS Improvement with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

trial status

Ph 1 trial SERHEMA-1 of AOP208 initiated in AML/MDS patients

Ph 1a Trial of TTX-MC138 in Metastatic solid tumors completed

Strong Enrollment and Dosing Momentum Reported in Ph 3 NSCLC Trial

Trial Discontinuation: External DMC recommends discontinuing Ph 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy + KEYTRUDA in 1L metastatic NSCLC with high PD-L1 expression

Business news

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

CytomX and Regeneron Expand Strategic Research Collaboration on Conditional Bispecific Therapeutics for Treating Cancer

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

Archive

2025

2024

2023

2022

2021

2020

2019

2018